News & Press

Read about recent events, essential information and the latest community news.

Member News

  • Retirement Announcement Thursday September 26th, 2019
    Dear CSAM Members: I recently announced to the CSAM Board of Directors that I will retire from my position as CSAM’s
  • DHCS is forming a new Behavioral Health Stakeholder Advisory Committee Tuesday April 30th, 2019
    CSAM members: Per the DHCS letter, several current DHCS behavioral health advisory groups are being merged
  • CSAM Receives State Targeted Response (STR) Grant Thursday March 01st, 2018
    The California Society of Addiction Medicine (CSAM) was selected by the California Department of Health Care Services (DHCS) to be part of a statewide collaborative project that includes UCLA Integrated Substance Abuse Programs, to increase access to addiction treatment, reduce unmet treatment need, and reduce opioid overdose related deaths through the provision of prevention, treatment and recovery activities ...


  • Governor Newsom Releases Master Plan for Tackling the Fentanyl and Opioid Crisis Monday March 20th, 2023
    Governor Newsom has invested over $1 billion to tackle the crisisThrough CalRx, California will seek to manufacture its own NaloxoneMaster Plan provides comprehensive approach to save more lives SAN DIEGO COUNTY – Today, following a visit to the San Ysidro Port of Entry, Governor Gavin Newsom released his administration’s Master Plan for Tackling the Fentanyl and ...
  • DEA Announces Important Change to Registration Requirement Tuesday January 31st, 2023
    On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.” All DEA registrants should be aware of the following: A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder. Going forward, all prescriptions for buprenorphine only require a standard DEA registration ...
  • End of Buprenorphine X-Waiver Wednesday January 25th, 2023
    After almost twenty years of intense medication specific government regulation buprenorphine is now just like other schedule III medications. The era of limited numbers of treatment slots that started at 30 patients per provider who had completed 8 hours of specific training, requirements to maintain lists of patients who received prescriptions and even in person visits ...
  • CSAM News – October 2022 Thursday October 06th, 2022
    The CSAM News was recently published! Featured articles include Conference Photos, Like Minded Docs, President’s Message, CSAM 50th Anniversary Bash & More! Read More…
  • CSAM Sponsored Legislation Heads to the Governor for Signature Wednesday August 03rd, 2022
    SACRAMENTO – The California Society of Addiction Medicine (CSAM) is pleased to announce that SB 57 (Wiener) was passed by the California Senate on August 1, and now heads to Governor Gavin Newsom for…
  • FDA Responds to Dr. Albanese’s April 19, 2021 Letter Tuesday July 20th, 2021
    The FDA has responded to Dr. Albanese’s letter to them from April 19, 2021. CLICK HERE to view the response!
  • FDA Commits to Evidence-Based Actions Aimed at Saving Lives and Preventing Future Generations of Smokers Friday April 30th, 2021
    Today, the U.S. Food and Drug Administration announced it is committing to advancing…
  • CSAM Newsletter – Vol. 45 Issue #2 (Winter 2020) Thursday December 31st, 2020
    The Newest Issue of the CSAM Newsletter is available. If you haven’t seen it yet, CLICK HERE to read it! This issue features the President’s message by CSAM President, Anthony Albanese; 2020 Public Policy Report; and Updates from the Education Committee!
  • The ABPM & ASAM Announce a Four-Year Extension of the Practice Pathway for Addiction Medicine Wednesday December 09th, 2020
    Chicago, IL, November 30, 2020: The American Board of Preventive Medicine (ABPM) and the American Society of Addiction Medicine (ASAM) jointly announced today the American Board of Medical Specialties’ (ABMS) approval of a four-year extension of the practice… Click Here to Read the entire article.
  • DEA Issues Interim Final Rule Clarifying MAT Dispensing Friday November 06th, 2020
    The Drug Enforcement Administration (DEA) issued an Interim Final Rule to clarify sections of the 2018 SUPPORT for Patients and Communities Act. The provisions in the Rule seek to further expand providers’ abilities to prescribe medication assisted treatment (MAT) to individuals suffering from opioid use disorders. Key items addressed in the Rule include: Providers can prescribe MAT for up ...

CSAM Newsletter